What is Pattern Bioscience?
Pattern Bioscience is a pioneering biotechnology firm specializing in rapid phenotypic identification and antimicrobial susceptibility testing (ID/AST). By leveraging innovative single-cell microbiology, the company provides diagnostic results in a matter of hours rather than days, a critical advancement for hospital settings where time-sensitive treatment decisions are paramount. Their technology directly addresses the global crisis of antibiotic misuse by enabling clinicians to prescribe targeted therapies more effectively, thereby improving patient outcomes and reducing the prevalence of resistant pathogens. As a leader in the diagnostic space, Pattern Bioscience is redefining the standard of care for common infection sites, positioning itself as an essential partner for healthcare providers worldwide.
How much funding has Pattern Bioscience raised?
Pattern Bioscience has raised a total of $137.7M across 5 funding rounds:
Series A
$6.4M
Series B
$15.4M
Series C
$28.7M
Stock/Share Issuance
$44.2M
Series D
$43M
Series A (2019): $6.4M, investors not publicly disclosed
Series B (2020): $15.4M led by Illumina Ventures and Omnimed Capital
Series C (2023): $28.7M supported by Omnimed Capital, Daleshaw, Illumina Ventures, and Antimicrobial Resistance Action Fund
Stock/Share Issuance (2025): $44.2M, investors not publicly disclosed
Series D (2025): $43M backed by Illumina Ventures and The AMR Action Fund
Key Investors in Pattern Bioscience
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs. They invest in biotechnology companies that are creating treatments for patients with life-threatening antimicrobial-resistant infections.
Omnimed Capital
Omnimed Capital is a strategic investment firm focused on supporting high-growth healthcare and medical technology companies. They provide the necessary capital and industry expertise to help firms scale their clinical solutions and improve patient care outcomes.
What's next for Pattern Bioscience?
With the successful closure of this latest funding round, Pattern Bioscience is poised to enter a phase of aggressive commercial expansion and product development. The strategic focus will likely center on scaling the deployment of its ID/AST platform across major healthcare networks, ensuring that its rapid diagnostic capabilities reach the clinical environments where they are most needed. Furthermore, the company is expected to continue its research and development efforts to broaden the scope of its diagnostic solutions, potentially addressing a wider array of infectious diseases. By maintaining its commitment to precision health and clinical efficiency, Pattern Bioscience is set to play a pivotal role in the future of infectious disease management and the broader fight against antimicrobial resistance.
See full Pattern Bioscience company page
